These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 28797729

  • 1. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
    Farzam N, Ramon-Saraf R, Banet-Levi Y, Lerner-Geva L, Ashkenazi S, Kubler-Kielb J, Vinogradov E, Robbins JB, Schneerson R.
    Vaccine; 2017 Sep 05; 35(37):4990-4996. PubMed ID: 28797729
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R, Israel Shigella Study Group.
    Pediatr Infect Dis J; 2003 Aug 05; 22(8):701-6. PubMed ID: 12913770
    [Abstract] [Full Text] [Related]

  • 3. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G, Keisari Y, Slepon R, Ashkenazi S, Cohen D.
    Vaccine; 1999 Aug 06; 17(23-24):3109-15. PubMed ID: 10462247
    [Abstract] [Full Text] [Related]

  • 4. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R.
    J Infect Dis; 1999 Jun 06; 179(6):1565-8. PubMed ID: 10228084
    [Abstract] [Full Text] [Related]

  • 5. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
    Passwell JH, Ashkenazi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, Robbins JB, Schneerson R, Israeli Shigella Study Group.
    Vaccine; 2010 Mar 02; 28(10):2231-2235. PubMed ID: 20056180
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.
    Citiulo F, Necchi F, Mancini F, Rossi O, Aruta MG, Gasperini G, Alfini R, Rondini S, Micoli F, Rappuoli R, Saul A, Martin LB.
    PLoS Negl Trop Dis; 2021 Oct 02; 15(10):e0009826. PubMed ID: 34644291
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
    Chisenga CC, Bosomprah S, Simuyandi M, Mwila-Kazimbaya K, Chilyabanyama ON, Laban NM, Bialik A, Asato V, Meron-Sudai S, Frankel G, Cohen D, Chilengi R.
    PLoS One; 2021 Oct 02; 16(5):e0252222. PubMed ID: 34043697
    [Abstract] [Full Text] [Related]

  • 11. Outer Membrane Vesicles Derived from Salmonella enterica Serotype Typhimurium Can Deliver Shigella flexneri 2a O-Polysaccharide Antigen To Prevent Shigella flexneri 2a Infection in Mice.
    Tian H, Li B, Xu T, Yu H, Chen J, Yu H, Li S, Zeng L, Huang X, Liu Q.
    Appl Environ Microbiol; 2021 Sep 10; 87(19):e0096821. PubMed ID: 34319809
    [Abstract] [Full Text] [Related]

  • 12. Shigella lipopolysaccharide antibodies in pediatric populations.
    Passwell JH, Freier S, Shor R, Farzam N, Block C, Lison M, Shiff E, Ashkenazi S.
    Pediatr Infect Dis J; 1995 Oct 10; 14(10):859-65. PubMed ID: 8584312
    [Abstract] [Full Text] [Related]

  • 13. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Kelly M, Janardhanan J, Wagh C, Verma S, Charles RC, Leung DT, Kamruzzaman M, Pansuriya RK, Chowdhury F, Vann WF, Kaminski RW, Khan AI, Bhuiyan TR, Qadri F, Kováč P, Xu P, Ryan ET.
    Vaccine; 2024 Oct 24; 42(24):126263. PubMed ID: 39217775
    [Abstract] [Full Text] [Related]

  • 14. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
    Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Bélot F, Cohen D, Sansonetti PJ, Mulard LA.
    J Immunol; 2009 Feb 15; 182(4):2241-7. PubMed ID: 19201878
    [Abstract] [Full Text] [Related]

  • 15. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
    Dharmasena MN, Osorio M, Takeda K, Stibitz S, Kopecko DJ.
    Clin Vaccine Immunol; 2017 Dec 15; 24(12):. PubMed ID: 29046309
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Shigella-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei.
    Clarkson KA, Porter CK, Talaat KR, Frenck RW, Alaimo C, Martin P, Bourgeois AL, Kaminski RW.
    mSphere; 2021 Aug 25; 6(4):e0012221. PubMed ID: 34259559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.